| Multiparameter functional diversity of human C2H2 zinc finger proteins FW Schmitges, E Radovani, HS Najafabadi, M Barazandeh, LF Campitelli, ... Genome research 26 (12), 1742-1752, 2016 | 173 | 2016 |
| Real‐world outcomes of FOLFIRINOX vs gemcitabine and nab‐paclitaxel in advanced pancreatic cancer: A population‐based propensity score‐weighted analysis KKW Chan, H Guo, S Cheng, JM Beca, R Redmond‐Misner, ... Cancer medicine 9 (1), 160-169, 2020 | 81 | 2020 |
| Developing a framework to incorporate real-world evidence in cancer drug funding decisions: the Canadian Real-world Evidence for Value of Cancer Drugs (CanREValue) collaboration K Chan, S Nam, B Evans, C de Oliveira, A Chambers, S Gavura, J Hoch, ... BMJ open 10 (1), e032884, 2020 | 49 | 2020 |
| Assessing the efficacy‐effectiveness gap for cancer therapies: a comparison of overall survival and toxicity between clinical trial and population‐based, real‐world data for … CM Phillips, A Parmar, H Guo, D Schwartz, W Isaranuwatchai, J Beca, ... Cancer 126 (8), 1717-1726, 2020 | 44 | 2020 |
| Cost-effectiveness analysis of pertuzumab with trastuzumab in patients with metastatic breast cancer WF Dai, JM Beca, C Nagamuthu, N Liu, C de Oliveira, CC Earle, ... JAMA oncology 8 (4), 597-606, 2022 | 18 | 2022 |
| Are population‐based patient‐reported outcomes associated with overall survival in patients with advanced pancreatic cancer? WF Dai, J Beca, H Guo, W Isaranawatchai, D Schwartz, R Naipaul, J Arias, ... Cancer medicine 9 (1), 215-224, 2020 | 16 | 2020 |
| Physician characteristics and decisions regarding cancer screening: a systematic review AI Neugut, SA MacLean, WF Dai, JS Jacobson Population Health Management 22 (1), 48-62, 2019 | 14 | 2019 |
| Comparison of use of neoadjuvant systemic treatment for breast cancer and short-term outcomes before vs during the COVID-19 era in Ontario, Canada S Habbous, X Tai, JM Beca, J Arias, MJ Raphael, A Parmar, A Crespo, ... JAMA Network Open 5 (8), e2225118-e2225118, 2022 | 13 | 2022 |
| Building a national reassessment process for oncology drugs: lessons learned by the Canadian Real-World Evidence for Value of Cancer Drugs (CanREValue) collaboration through a … WF Dai, E Craig, B Fraser, A Chambers, H Mai, MB Brown, CC Earle, ... Current Oncology 28 (6), 4645-4654, 2021 | 13 | 2021 |
| Real-world comparative effectiveness of second-line ipilimumab for metastatic melanoma: a population-based cohort study in Ontario, Canada WF Dai, JM Beca, R Croxford, W Isaranawatchai, IB Menjak, TM Petrella, ... BMC cancer 20, 1-10, 2020 | 13 | 2020 |
| Real-world cost-effectiveness of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: population-based retrospective cohort … RE Pataky, J Beca, D Tran, WF Dai, E Dvorani, W Isaranuwatchai, ... MDM Policy & Practice 6 (1), 23814683211021060, 2021 | 12 | 2021 |
| Use of real-world evidence in cancer drug funding decisions in Canada: A qualitative study of stakeholders’ perspectives M Clausen, C Mighton, R Kiflen, A Sebastian, WF Dai, RE Mercer, ... Canadian Medical Association Open Access Journal 8 (4), E772-E778, 2020 | 10 | 2020 |
| Considerations for developing a reassessment process: report from the Canadian real-world evidence for value of cancer drugs (CanREValue) Collaboration’s Reassessment and … WF Dai, V Arciero, E Craig, B Fraser, J Arias, D Boehm, N Bosnic, ... Current Oncology 28 (5), 4174-4183, 2021 | 9 | 2021 |
| Improved survival in overweight and obese patients with aggressive B-cell lymphoma treated with rituximab-containing chemotherapy for curative intent JKR Stevenson, Y Qiao, KKW Chan, J Beca, W Isaranuwatchai, H Guo, ... Leukemia & lymphoma 60 (6), 1399-1408, 2019 | 8 | 2019 |
| Real-World Cost-Effectiveness of First-Line Gemcitabine Plus Nab-Paclitaxel vs FOLFIRINOX in Patients With Advanced Pancreatic Cancer V Arciero, J Luo, A Parmar, WF Dai, JM Beca, MJ Raphael, ... JNCI Cancer Spectrum 6 (4), pkac047, 2022 | 7 | 2022 |
| Comparative effectiveness and safety of pertuzumab and trastuzumab plus chemotherapy vs trastuzumab plus chemotherapy for treatment of metastatic breast cancer WF Dai, JM Beca, C Nagamuthu, N Liu, C de Oliveira, CC Earle, ... JAMA network open 5 (2), e2145460-e2145460, 2022 | 7 | 2022 |
| Real-world safety of bevacizumab with first-line combination chemotherapy in patients with metastatic colorectal cancer: Population-based retrospective cohort studies in three … JM Beca, WF Dai, RE Pataky, D Tran, E Dvorani, W Isaranuwatchai, ... Clinical Oncology 34 (1), e7-e17, 2022 | 7 | 2022 |
| Real‐world, population‐based cohort study of toxicity and resource utilization of second‐line ipilimumab for metastatic melanoma in Ontario, Canada WF Dai, J Beca, R Croxford, W Isaranuwatchai, IB Menjak, TM Petrella, ... International Journal of Cancer 148 (8), 1910-1918, 2021 | 6 | 2021 |
| Association between primary heath care and dental service use among supportive housing tenants with behavioral health conditions G Hall, WF Dai, S Lim Community Dentistry and Oral Epidemiology 49 (1), 70-77, 2021 | 6 | 2021 |
| Hibiscus latent Fort Pierce virus in Brazil and synthesis of its biologically active full-length cDNA clone R Gao, S Niu, W Dai, E Kitajima, SM Wong Virus Genes 52, 754-757, 2016 | 5 | 2016 |
